Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Reaffirmed by Rodman & Renshaw

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reiterated by research analysts at Rodman & Renshaw in a note issued to investors on Tuesday, Benzinga reports. They currently have a $14.00 target price on the stock.

Several other brokerages also recently issued reports on CGTX. Chardan Capital began coverage on Cognition Therapeutics in a report on Thursday, June 6th. They set a “buy” rating and a $11.00 price target for the company. HC Wainwright assumed coverage on Cognition Therapeutics in a research report on Wednesday, May 29th. They issued a “buy” rating and a $10.00 price objective on the stock. B. Riley reissued a “buy” rating and issued a $5.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Finally, Oppenheimer reissued an “outperform” rating and issued a $9.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $9.17.

Cognition Therapeutics Trading Down 2.7 %

Shares of Cognition Therapeutics stock opened at $1.77 on Tuesday. The stock has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $2.01. Cognition Therapeutics has a 12-month low of $0.90 and a 12-month high of $2.95. The company has a market capitalization of $70.90 million, a P/E ratio of -1.92 and a beta of 1.48.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts predict that Cognition Therapeutics will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. AWM Investment Company Inc. purchased a new position in shares of Cognition Therapeutics during the 1st quarter valued at $1,183,000. Hohimer Wealth Management LLC purchased a new position in shares of Cognition Therapeutics during the 1st quarter valued at $410,000. CM Management LLC purchased a new position in shares of Cognition Therapeutics during the 1st quarter valued at $318,000. Twin Focus Capital Partners LLC purchased a new position in shares of Cognition Therapeutics during the 4th quarter valued at $173,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cognition Therapeutics during the 4th quarter valued at $102,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.